Table 2.
Tolerogenic vaccination with “IFN-β + MOG in Alum” elicits tolerance in 2D2 TCR transgenic mice.
| Figure | Groupa | Incidence | Attrition | Cumulative EAE |
P value | P value | Maximal EAE |
P value | P value | Maximum Weight Loss |
P value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7F | (a) IFN-β + MOG in Alum (3x) | 1/3 | 0/3 | 0.2 ± 0.2 | 0.017 | 0.000 | 0.2 ± 0.2 | 0.020 | 0.000 | 1.2 ± 1.3% | 0.019 |
| 7F | (b) IFN-β + MOG in Alum (2x) | 2/3 | 0/3 | 25.8 ± 13.1 | ns | 2.2 ± 1.1 | ns | 13.3 ± 4.5% | |||
| 7F | (c) IFN-β + MOG in Alum (1x) | 1/3 | 0/3 | 0.3 ± 0.3 | 0.022 | 0.2 ± 0.2 | 0.020 | 2.6 ± 1.1% | |||
| 7F | (d) Saline in Alum (3x) | 3/3 | 2/3 | 64.5 ± 11.9 | ns | * | 4.7 ± 0.3 | * | * | 25.6 ± 1.6% | * |
| 7F | (e) MOG in Alum (3x) | 3/3 | 2/3 | 41.2 ± 17.4 | ns | 3.7 ± 1.3 | ns | 20.4 ± 6.7% | |||
| 7F | (f) Naive | 6/6 | 3/6 | 56.3 ± 11.9 | * | 3.5 ± 0.6 | ns | 10.0 ± 5.0% | |||
| 8 | (g) IFN-β + MOG in Alum (3x) | 8/8 | 0/8 | 2.9 ± 0.9 | 0.002 | 0.005 | 0.6 ± 0.1 | 0.003 | 0.003 | 4.5 ± 1.2% | 0.000 |
| 8 | (h) IFN-β + OVA in Alum (3x) | 8/8 | 2/8 | 31.8 ± 5.4 | * | 3.9 ± 0.3 | * | 24.7 ± 3.5% | * | ||
| 8 | (i) MOG in Alum (3x) | 6/6 | 1/6 | 38.2 ± 4.3 | * | 4.3 ± 0.3 | * | 29.9 ± 2.7% | * |
a
These data are portrayed graphically in Figures 7F and 8A–B. The experimental approach is described in the figure legends. Nonparametric ANOVA based on ranked scores was used to assess group differences in mean cumulative scores and mean maximal scores relative to the comparator group
*
whereas parametric ANOVA was used to assess weight loss (Bonferroni Post-Hoc test; a–e versus f; g versus h and i). An Independent Samples T-test was used to analyze differences in data compiled for tolerogenic vaccination (a–c) versus control groups (d–f).